Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy

Maturitas

Volumn 46, Issue 4, 2003, Pages 295-299

  Hsu, Shih Cheng ^a   Long, Cheng Yu ^a   Yang, Cheng Hui ^b   Wu, Ching Hu ^b   Chen, Chien Hsin ^a   Liu, Fang I ^a,c  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Cox 2; Endometrium; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; CYCLOOXYGENASE 2; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION;

EQUIDAE;

EID: 0242643646     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00218-4     Document Type: Article

References (34)

1. Hammond C.B. Menopause and hormone replacement therapy: an overview. Obstet. Gynecol. 87:1996;2s-15s.
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288:2002;321-333.
3. Smith D.C., Prentice R., Thompson D.J., Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. New Engl. J. Med. 293:1975;1164-1167.
4. Gambrell R.D. Jr. Prevention of endometrial cancer with progestogens. Maturitas. 8:1986;159-168.
5. Persson I., Adami H.O., Bergkvist L., et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens. Results of a prospective study. Br. Med. J. 298:1989;147-151.
6. Ravnikar V.A. Barriers for taking long-term hormone replacement therapy: why do women not adhere to therapy. Eur. Menopause J. 3:(Suppl. 2):1996;90-93.
7. Crofford L.J. Cox-1 and Cox-2 tissue expression: implications and predictions. J. Rheumatol. 24:(Suppl. 49):1997;15-19.
8. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90:1998;455-460.
9. Sales K.J., Katz A.A., Howard B., Soeters R.P., Millar R.P., Jabbour H.N. Cyclooxygenase-1 is upregulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 62:2002;424-432.
10. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
11. Sano H., Kawahito Y., Wilder R.L., et al. Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
12. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol. Oncol. 76:2000;320-325.
13. Subbaramaiah K., Zakim D., Weksler B.B., Dannenberg A.J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. 216:1997;201-210.
14. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS 398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249.
15. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146.
16. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Jr. Aspirin use and risk of fatal cancer. Cancer Res. 53:1993;1322-1327.
17. Marions L., Danielsson K.G. Expression of cyclooxygenase in human endometrium during the implantation period. Mol. Hum. Reprod. 5:1999;961-965.
18. Uotila P.J., Erkkola R.U., Klemi P.J. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann. Med. 34:2002;428-433.
19. Fujiwaki R., Iida K., Kanasaki H., Ozaki T., Hata K., Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum. Pathol. 33:2002;213-219.
20. Cao Q.J., Einstein M.H., Anderson P.S., Runowicz C.D., Balan R., Jones J.G. Expression of Cox-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int. J. Gynecol. Pathol. 21:(2):2002;147-154.
21. Tong B.J., Tan J., Tajeda L., et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-d in human endometrial adenocarcinoma. Neoplasia. 2:2000;483-490.
22. Jabbour H.N., Milne S.A., Williams A.R.W., Anderson R.A., Boddy S.C. Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br. J. Cancer. 85:(7):2001;1023-1031.
23. Munir I., Fukunaga K., Kanasaki H., et al. Expression of cyclooxygenase 2 by prostaglandin E2 in human endometrial adenocarcinoma cell line HEC-1B. Biol. Reprod. 63:2000;933-941.
24. Hsu S.M., Raine L. Delellis R.A. The use of avidin-biotin-peroxidase complex (ABC) in diagnostic and research pathology, in advances in immunohistochemistry. 1984;Year Book Medical, Chicago.
25. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J. Am. Med. Assoc. 275:1996;370-375.
26. Whitehead M.L., Townsend P.L., Pryce-Davies J., Ryder T.A., King J.B. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New Engl. J. Med. 305:1981;1599-1605.
27. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1997;458-461.
28. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91:1999;1131-1137.
29. Moyer D.L., de Lignieres B., Driguez P., Pez J.P. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil. Steril. 59:1993;992-997.
30. King R.J.B., Whitehead M.I., Campbell S., et al. Biochemical studies on the endometrium from postmenopausal women receiving hormone replacement therapy. Postgrad. Med. J. 54:1978;65-68.
31. Casper R.F. Regulation of estrogen/progestogen receptors in the endometrium. Int. J. Fertil. Menopausal Stud. 41:1996;16-21.
32. Otto J.C., Smith W.L. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J. Biol. Chem. 269:1994;19868-19875.
33. Dubois R.N., Tsujii M., Bishop P., Awad J.A., Makita K., Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol. 266:1994;G822-G827.
34. Giardiello F.M., Offerhaus G.J., DuBois R.N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer. 31A:1995;1071-1076.